ClinicalTrials.gg

Program

zatolmilast

Also written as “BPN14770”, “BPN14770/ zatolmilast” and “Zatolmilast/ BPN14770”.

Its studies are mostly in Fragile X Syndrome · Alzheimer Disease · Neurodevelopmental Disorders · Renal Insufficiency, led by Shionogi.

Furthest: phase 3, since Dec 15, 202113 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi132 open or runningphase 3since Dec 15, 2021Jan 4, 2016Sep 30, 2027phase 3 · NCT05367960

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 4, 2016First study: phase 1 study in Alzheimer DiseaseFirst studyNCT02648672 · 32 enrolled · United States
  2. Jul 19, 2016Phase 1 study in Alzheimer DiseaseNCT02840279 · 77 enrolled · United States
  3. Jan 17, 2017Phase 1 study in Alzheimer DiseaseNCT03030105 · 38 enrolled · United States
  4. May 25, 2018Phase 2 study in Fragile X SyndromeNCT03569631 · 30 enrolled · United States
  5. Jan 18, 2019Phase 2 study in Alzheimer DiseaseNCT03817684 · 255 enrolled · United States
  6. Aug 2, 2019Phase 1 study in To Determine Brain Target Occupancy of BPN14770NCT04044781 · United States
  7. Dec 15, 2021Phase 3 study in Fragile X SyndromeNCT05163808 · 163 enrolled · United States
  8. Apr 27, 20222 phase 3 studies in Fragile X SyndromeNCT05358886, NCT05367960
  9. Dec 2, 2024Phase 2 study in Jordan's SyndromeNCT06717438 · 30 enrolled · United States
  10. Jun 2, 20253 phase 1 studiesNCT07012005, NCT07011992, NCT07018492

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in Fragile X SyndromeNCT05367960
  2. Dec 31, 2027Primary completion: phase 2 study in Jordan's SyndromeNCT06717438

TargetBeta

PDE4D →read by rule
“Phosphodiesterase 4D inhibitor”ChEMBL 37, by rule

Other programs on PDE4D

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
apremilastruleAmgenphase 448
ensifentrineruleMerckphase 317
difamilastruleOtsukaphase 316
tanimilastruleChiesi Farmaceuticiphase 315

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07018492Hepatic Impairment · United States1CompletedNov 26, 202532
NCT07012005Renal Insufficiency · United States1CompletedDec 15, 202514
NCT07011992Healthy Participants · United States1CompletedJul 31, 202512
NCT06717438Jordan's Syndrome · United States2Active, not recruitingDec 31, 202730
NCT05367960Fragile X Syndrome · United States3Active, not recruitingSep 30, 2027314
NCT05358886Fragile X Syndrome · United States3CompletedJul 18, 2025171
NCT05163808Fragile X Syndrome · United States3CompletedSep 2, 2025163
NCT04044781To Determine Brain Target Occupancy of BPN14770 · United States1WithdrawnApr 30, 20200
NCT03817684Alzheimer Disease · United States2CompletedFeb 4, 2020255
NCT03569631Fragile X Syndrome · United States2CompletedJul 31, 202030
NCT03030105Alzheimer Disease · United States1CompletedMay 201738
NCT02840279Alzheimer Disease · United States1CompletedNov 201677
NCT02648672Alzheimer Disease · United States1CompletedFeb 201632

How it is read

Names in the registry

  • “BPN14770”, 9 entries
  • “zatolmilast”, 1 entry
  • “BPN14770/ zatolmilast”, 1 entry
  • “Zatolmilast/ BPN14770”, 1 entry
  • “BPN14770, T2310”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.